FDA officials argue over safety of new arthritis drug.

Ray Moynihan*

*Corresponding author for this work

Research output: Contribution to journalArticleProfessional

5 Citations (Scopus)

Abstract

An external advisory panel to the US Food and Drug Administration last week rejected calls from FDA safety experts to withdraw a drug for rheumatoid arthritis from the market.
Original languageEnglish
Pages (from-to)565-565
Number of pages1
JournalBMJ (Clinical research ed.)
Volume326
Issue number7389
DOIs
Publication statusPublished - 15 Mar 2003

Fingerprint

Dive into the research topics of 'FDA officials argue over safety of new arthritis drug.'. Together they form a unique fingerprint.

Cite this